Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-Year results of a propensity score matching comparison: the BVS-examination study (Bioresorbable Vascular Scaffold-a clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial infarction)

JACC: Cardiovascular Interventions

Volumn 8, Issue 1, 2015, Pages 189-197

  Brugaletta, Salvatore ^a   Gori, Tommaso ^b   Low, Adrian F ^c   Tousek, Petr ^d   Pinar, Eduardo ^e   Gomez Lara, Josep ^f   Scalone, Giancarla ^a   Schulz, Eberhard ^b   Chan, Mark Y ^c   Kocka, Viktor ^d   Hurtado, Jose ^e   Gomez Hospital, Juan Antoni ^f   Münzel, Thomas ^b   Lee, Chi Hang ^c   Cequier, Angel ^f   Valdés, Mariano ^e   Widimsky, Petr ^d   Serruys, Patrick W ^g   Sabaté, Manel ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^c DEPARTMENT OF CARDIOLOGY   (Singapore)

^d CHARLES UNIVERSITY   (Czech Republic)

^e HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^f HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^g ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Absorb; Everolimus eluting stent; STEMI

Indexed keywords

EVEROLIMUS; CARDIOVASCULAR AGENT; METAL; RAPAMYCIN;

ADULT; AGED; ARTICLE; BARE METAL STENT; BIORESORBABLE VASCULAR STENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ELUTING CORONARY STENT; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROPENSITY SCORE; REVASCULARIZATION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; BIODEGRADABLE IMPLANT; CLINICAL TRIAL; COMPARATIVE STUDY; CORONARY THROMBOSIS; DEVICES; DRUG ELUTING STENT; FACTUAL DATABASE; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MYOCARDIAL INFARCTION; PROPORTIONAL HAZARDS MODEL; PROSTHESIS; RECURRENT DISEASE; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICAL MODEL; TIME; TREATMENT OUTCOME;

ABSORBABLE IMPLANTS; ADULT; AGED; CARDIOVASCULAR AGENTS; CORONARY THROMBOSIS; DATABASES, FACTUAL; DRUG-ELUTING STENTS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MALE; METALS; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; PROSTHESIS DESIGN; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; SIROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84921407125     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2014.10.005     Document Type: Article

References (26)

1. Dudek D, Onuma Y, Ormiston JA, Thuesen L, Miquel-Hebert K, Serruys PW. Four-year clinical follow-up of the ABSORB everolimus-eluting bioresorbable vascular scaffold in patients with de novo coronary artery disease: the ABSORB trial. EuroIntervention 2012;7:1060-1.
2. Brugaletta S, Garcia-Garcia HM, Onuma Y, Serruys PW. Everolimus-eluting ABSORB bioresorbable vascular scaffold: present and future perspectives. Expert Rev Med Devices 2012;9:327-38.
3. Brugaletta S, Radu MD, Garcia-Garcia HM, et al. Circumferential evaluation of the neointima by optical coherence tomography after ABSORB bioresorbable vascular scaffold implantation: can the scaffold cap the plaque? Atherosclerosis 2012;221:106-12.
4. Gori T, Schulz E, Hink U, et al. Early outcome after implantation of Absorb bioresorbable drug-eluting scaffolds in patients with acute coronary syndromes. EuroIntervention 2014;9:1036-41.
5. Fernandez-Rodriguez D, Brugaletta S, Otsuki S, Sabate M. Acute ABSORB bioresorbable vascular scaffold thrombosis in ST-segment elevation myocardial infarction: to stent or not to stent? EuroIntervention 2014;10:600, discussion 600.
6. Ishibashi Y, Onuma Y, Muramatsu T, et al. Lessons learned from acute and late scaffold failures in the ABSORB EXTEND trial. Euro-Intervention 2014;10:449-57.
7. Sabate M, Cequier A, Iniguez A, et al. Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial. Lancet 2012;380:1482-90.
8. Raber L, Kelbaek H, Ostojic M, et al. Effect of biolimus-eluting stents with biodegradable polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial infarction: the COMFORTABLE AMI randomized trial. JAMA 2012;308:777-87.
9. Sabate M, Raber L, Heg D, et al. Comparison of newer-generation drug-eluting with bare-metal stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of the EXAMINATION (clinical Evaluation of the Xience-V stent in Acute Myocardial INfArcTION) and COMFORTABLE-AMI (Comparison of Biolimus Eluted From an Erodible Stent Coating With Bare Metal Stents in Acute ST-Elevation Myocardial Infarction) trials. J Am Coll Cardiol Intv 2014;7:55-63.
10. Palmerini T, Biondi-Zoccai G, Della Riva D, et al. Clinical outcomes with drug-eluting and bare-metal stents in patients with ST-segment elevation myocardial infarction: evidence from a comprehensive network meta-analysis. J Am Coll Cardiol 2013;62:496-504.
11. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007;115:2344-51.
12. Sabate M, Cequier A, Iniguez A, et al., in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. Rationale and design of the EXAMINATION trial: a randomised comparison between everolimus-eluting stents and cobalt-chromium bare-metal stents in ST-elevation myocardial infarction. EuroIntervention 2011;7:977-84.
13. Austin PC, Mamdani MM. A comparison of propensity score methods: a case-study estimating the effectiveness of post-AMI statin use. Stat Med 2006;25:2084-106.
14. Serruys PW, Garcia-Garcia HM, Onuma Y. From metallic cages to transient bioresorbable scaffolds: change in paradigm of coronary revascularization in the upcoming decade? Eur Heart J 2012;33:16-25.
15. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006;48:193-202.
16. Diletti R, Karanasos A, Muramatsu T, et al. Everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with ST-segment elevation myocardial infarction: BVS STEMI first study. Eur Heart J 2014;35:777-86.
17. Kocka V, Maly M, Tousek P, et al. Bioresorbable vascular scaffolds in acute ST-segment elevation myocardial infarction: a prospective multicentre study 'Prague 19.' Eur Heart J 2014;35:787-94.
18. Jaguszewski M, Wyss C, Alibegovic J, Luscher TF, Templin C. Acute thrombosis of bioabsorbable scaffold in a patient with acute coronary syndrome. Eur Heart J 2013;34:2046.
19. Spaulding C, Henry P, Teiger E, et al. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med 2006;355:1093-104.
20. Stone GW, Lansky AJ, Pocock SJ, et al. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. N Engl J Med 2009;360:1946-59.
21. Bangalore S, Toklu B, Amoroso N, et al. Bare metal stents, durable polymer drug eluting stents, and biodegradable polymer drug eluting stents for coronary artery disease: mixed treatment comparison meta-analysis. BMJ 2013;347:f6625.
22. Capodanno D, Gori T, Nef H, et al. Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. EuroIntervention 2014 Jul 18 [E-pub ahead of print].
23. Ormiston JA, Serruys PW, Regar E, et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet 2008;371:899-907.
24. Muramatsu T, Onuma Y, Garcia-Garcia HM, et al. Incidence and short-term clinical outcomes of small side branch occlusion after implantation of an everolimus-eluting bioresorbable vascular scaffold: an interim report of 435 patients in the ABSORB-EXTEND single-arm trial in comparison with an everolimus-eluting metallic stent in the SPIRIT first and II trials. J Am Coll Cardiol Intv 2013;6:247-57.
25. Diletti R, Serruys PW, Farooq V, et al. ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design. Am Heart J 2012;164:654-63.
26. Serruys PW, Ormiston JA, Onuma Y, et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet 2009;373:897-910.